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Introduction
Congenital adrenal hyperplasia (CAH) is 
a group of inherited autosomal recessive disorders 
that affect adrenal glands, characterized by 
impaired cortisol synthesis and adrenal androgen 
excess caused by a deficiency in one of the 
enzymes necessary for the synthesis of cortisol, 
aldosterone, or both of them. CAH is mostly caused 
by CYP21A2 mutations, the gene responsible for 
21 hydroxylase enzyme synthesis, and precursor 
for cortisol and aldosterone [1], [2]. Depending on 
the deficiency of enzyme, the CAH can be classic 
(complete or almost complete enzyme deficiency) 
or non-classic or mild form (some enzyme activity is 
retained) [3], [4]. Due to the CYP21A2 deficiency or 
21 hydroxylase enzyme, the defective conversion of 
17-hydroxyprogesterone to 11-deoxycortisol results in 
decreased cortisol synthesis and therefore increased 
adrenocorticotropin hormone (ACTH) secretion that 
stimulates the adrenal cortex to accumulates cortisol 
precursors that are diverted into excessive androgens 
production, responsible for symptoms of non-classic 
CAH. In patients with the non-classic CAH, although 
enzymatic activity is reduced, it is sufficient to keep 
up normal glucocorticoid and mineralocorticoid 
production at the expense of excessive androgen 
production.
Classic CAH can be salt-wasting or simple 
virilizing type. The incidence of CAH ranges from 
1:10000 to 1:20000 births [5], [6]. The non-classic 
CAH disease is mild and usually can be asymptomatic 
at birth [7]; symptoms are presented more often in 
late childhood, adolescence, or later in life caused by 
excessive androgen secretion [8]. Non-classic CAH 
from 21-OH deficiency is much more common than 
classic CAH [9], with a reported prevalence of 0.1–0.4% 
in the general population [10]. It is also more frequent 
in certain ethnicities such as a Mediterranean, Middle-
Eastern Ashkenazi Jewish, and Indian population [11]. 
Around 95% of non-classic CAH are due to 21-OH 
deficiency [12].
We present a patient with severe clinical signs 
of hyperandrogenism.
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Abstract
BACKGROUND: Non-classic congenital adrenal hyperplasia (NCAH) is a relatively common disorder, but very often, 
it remains undiagnosed. Clinical appearance of NCAH can be asymptomatic at birth. Symptoms are presented more 
often in late childhood, adolescence, or later in life caused by excessive androgen secretion. 
CASE REPORT: We report the case of 27-year-old girl with 2 years history of high-grade of hirsutism, hair loss on 
the front of scalp with female pattern hair loss, (grade II according to Ludwig scale), breast volume reduction, weight 
loss (15 kg), depression, but without menstrual disorders, normal blood pressure, and usage of oral contraceptives 
for more than 1 year without any improvement. We did blood tests for hormonal protocol for hyperandrogenemia and 
we found these values high 17 (OH) progesterone and all other androgen hormones. After these examinations, the 
patient was diagnosed with a non-classic form of CAH. 
CONCLUSION: Treatment with corticosteroids and other necessary treatment improved clinical and hormonal 
features.
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Case Report
A 27-year-old Caucasian woman came to the 
hospital in the winter of 2016 with a 2 years history 
of increased hair growth of face (Figure 1), chest, 
lower abdomen, lower spine, arm and legs with a high 
scale of hirsutism, without menstrual disorders and 
clitoromegaly, hair loss, breast volume reduction, weight 
loss (15 kg), and depression in admission. Facial hair 
growth required shaving 2–3 times/week. She used to 
take oral contraceptives (OCs) for more than 1 year 
without any clinical improvement.
In physical examination, she had heart rate 
80/min, blood pressure 120/80 mmHg, and hirsutism 
was evaluated based on Ferriman–Gallwey score which 
resulted very high (result = 23). Hair loss was centered 
in the frontal region of the scalp (male pattern hair loss 
grade II according to Ludwig scale), (Figures 2). In 
the ultrasound, ovaries were without cystic changes. 
Magnetic resonance imaging of abdomen showed 
slightly hyperplasia of both adrenal glands without 
any other changes in abdominal organs. In laboratory 
analyses, total testosterone was 93 ng/dL (<75), 
dehydroepiandrosterone sulfate (DHEA-S) 639.9 pg/mL 
(35–430 pg/ml), 17- hydroxyprogesterone 6.59 nmol/L 
(0.1–0.8), androstenedione 10 ng/mL (0.4–3.4), 
ACTH 79.7 pg/ml (5.0–46.0), cortisol 553.6 nmol/L 
(138.0–690.0), prolactin 20 ng/mL (0–20), and 
luteinizing hormone/follicle-stimulating hormone 2.1 
(>2.5 positive for polycystic ovarian syndrome [PCOS]). 
It was not possible to be realized genetic testing in our 
country but based on clinical and laboratory analyses, 
the diagnosis of non-classic CAH was made.
Dexamethasone 0.25 mg once daily was 
started in midnight for 1 month following 0.5 mg for 
next 2 months and spironolactone 50 mg twice a day. 
All signs of hirsutism were absent (hirsutism according 
to Ferriman–Gallwey score after treatment resulted 0) 
and androgenic hormones were improved (Table 1) 
after 3 months of treatment (Figures 1 and 2). The 
patient continues to be treated at lower doses of both 
drugs in continuation. Periodically potassium analyses 
were done which always was in normal values. All the 
patient’s photos used in the presentation are with the 
patient’s permission and written informed consent was 
done.
Discussion
We present a patient with a high score of 
hirsutism, hair loss, and high level of androgenic 
hormones. Usually, patients with non-classic CAH often 
have clinical manifestations of hyperandrogenism such 
as early pubarche, acne, hirsutism, or oligomenorrhoea/
amenorrhoea. Female adolescents may present with 
signs of hyperandrogenism such as acne, hirsutism, 
and alopecia. Alopecia in women with CAH is of the 
male pattern type of hair loss [13].
It is known that a basal, morning serum 
17-hydroxyprogesterone value (drawn in the early 
follicular phase in cycling women) greater than 
200 ng/dL (6 nmol/L) strongly suggests the diagnosis. 
Although confirmation of the diagnosis is needed, 
250 mg of cosyntropin i.v. is suggested to do [14]. In 
our patients, 17(OH) progesterone was sufficiently for 
starting the treatment for non-classic CAH (NCAH).
During the diagnosis, it has to be excluded the 
most common form of androgen excess as is PCOS.
Table 1: The level of hormones before and after the treatment
Hormones In admission 3 months after 
the treatment
Reference values
17 (OH) progesterone 6.59 0.80 0.1–0.8 nmol/L follicular phase
Androstenedione 10 2.2 Female 0.40–3.40 ng/mL
Testosterone 93.0 22.6 <75 ng/dL
DHEA-S 639.9 145.3 35.0–430.0 pg/mL
ACTH 79.7 38.0 5.0–46.0 pg/mL
Cortisol 553.6 23.4 138.0–690.0 nmol/L
ACTH: Adrenocorticotropin hormone, DHEA-S: Dehydroepiandrosterone sulfate.
The origin of hyperandrogenemia in 
women may be from an ovarian or adrenal source. 
DHEA-S, DHEA, androstenedione, testosterone, and 
dihydrotestosterone are the major circulating androgens 
in women. DHEA is produced 50% in the adrenal gland, 
30% from conversion of DHEA-S, and 20% in the ovary. 
Whereas, both glands equally produce androstenedione 
Figure 1: Hirsutism in face areas in admission and after the treatment Figure 2: Hair in admission, after 3 and 12 months of the treatment
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and testosterone in the adrenal gland (25%), in 
the ovaries (25%), and 50% from androstenedione 
conversion [15]. Dihydrotestosterone is classically an 
intracellular androgen. In this case, DHEA-S along with 
testosterone was elevated. Our patient had all three of 
them.
Another important analysis for the diagnosis is a 
molecular genetic analysis which enables confirmation of 
the diagnosis and predicting treatment progress except 
the level of 17 (OH) progesterone. ACTH (cosyntropin) 
stimulation test continues to be considered as gold 
standard for distinguishing 21-hydroxylase deficiency 
from other enzyme defects [13].
Treatment with glucocorticoids is essential 
since one-third of patients with NCAH have partial 
cortisol insufficiency [16]. Antiandrogenic drugs like 
spironolactone might be useful as additional therapy but 
with it has to be aware of their potential teratogenicity, 
and they usually are accompanied with OCs. It is 
recommended regular clinical monitoring of glucocorticoid 
treatment to avoid long-term complications such as 
insulin resistance, hypertension, obesity, osteoporosis, 
fractures, and secondary cortisol insufficiency [17]. As 
in our case, although not for a long time, almost 3 years 
in the treatment, none of the complications are present, 
and she is living a normal life.
Conclusions
In the undeveloped and developing countries 
where more sophisticated genetic examination are 
missing or even gold standard like synacthen test is 
not often available, 17(OH) progesterone analyses are 
sufficient to start the treatment for NCAH.
Patients with NCAH with a severe level of 
hirsutism for a short period of time from starting the 
treatment can reach an excellent response shown in 
clinical and laboratory data.
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